Growth Drivers of the Plasma Fractionation Industry: A Global Perspective

The global plasma fractionation market, valued at $36.8 billion in 2024, is projected to reach $50.7 billion by 2030, growing at a 5.5% CAGR, according to P&S Intelligence. The market’s expansion is primarily driven by the aging population, which is more susceptible to rare disorders that require plasma derivatives for treatment.

The COVID-19 pandemic led to a surge in the demand for convalescent plasma, significantly boosting market growth during this period.

The immunoglobulins segment is anticipated to grow at a notable rate of 7.9% over the coming years. This growth can be attributed to the availability of plasma-derived immunoglobulins and their rising use, particularly for treating immune system disorders and chronic inflammatory demyelinating polyneuropathy.

Immunoglobulins serve as a primary treatment for various neurological, hematological, and immunological conditions, and the prevalence of these disorders has increased over the years. Additionally, the rising number of people with immunodeficiencies has spurred genetic research to diagnose these conditions, thus driving the demand for clinical immunoglobulins and other plasma-based therapies.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/plasma-fractionation-market/report-sample

In 2022, the neurology segment held the largest share of the plasma fractionation market, accounting for approximately 28% of the revenue. This is due to the increased use of plasma-derived products in treating neurological disorders. For instance, around 795,000 Americans suffer from strokes annually, with the risk increasing significantly after age 55, thus fueling the demand for plasma-based therapeutic products.

The oncology segment is expected to record the fastest growth in the coming years, driven by the growing acceptance of plasma therapies to treat challenging cancer targets.

Ion exchange chromatography led the technology segment with the highest revenue share in 2022. This method has advanced the production of new therapeutic plasma byproducts, including anticoagulants, protease inhibitors, and coagulation factors.

North America dominated the plasma fractionation market, holding around 55% of the revenue share. This can be attributed to ongoing advancements in pharmaceutical R&D, a rising number of plasma collection centers, increased paid plasma donation activities, a growing population of hemophilia patients, and the presence of key industry players. Europe ranked second, driven by a higher incidence of immunodeficiency and bleeding disorders, leading to increased investments in plasma fractionation systems.

The expanding use of immunoglobulins across various therapies, the development of plasma collection networks, and the rising incidence of respiratory issues are expected to propel the growth of the plasma fractionation market in the years ahead.

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

Contact:
Chandra Mohan
AVP - Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com